Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transforming ovarian cancer care by targeting minimal residual disease.
Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Jazaeri AA, et al. Among authors: aghajanian c. Med. 2023 Nov 10;4(11):755-760. doi: 10.1016/j.medj.2023.08.004. Med. 2023. PMID: 37951209
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Matulonis UA, et al. Among authors: aghajanian c. Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672. Ann Oncol. 2017. PMID: 27993796 Free PMC article. Clinical Trial.
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.
Manning-Geist B, Gordhandas S, Hodgson A, Zhou QC, Iasonos A, Chi DS, Ellenson L, Aghajanian CA, Abu-Rustum NR, Leitao M, Long K, Rubinstein MM, Sonoda Y, Alektiar K, Weigelt B, Zivanovic O, Grisham RN. Manning-Geist B, et al. Among authors: aghajanian ca. Int J Gynecol Cancer. 2022 Dec 5;32(12):1576-1582. doi: 10.1136/ijgc-2022-003935. Int J Gynecol Cancer. 2022. PMID: 36368707 Free PMC article.
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, Long Roche K, Zivanovic O, Chi DS, Aghajanian C, Grisham RN. Manning-Geist BL, et al. Among authors: aghajanian c. Cancer. 2023 Jul 1;129(13):2004-2012. doi: 10.1002/cncr.34753. Epub 2023 Mar 23. Cancer. 2023. PMID: 36951509
Landscape of chromatin remodeling gene alterations in endometrial carcinoma.
Momeni-Boroujeni A, Vanderbilt C, Yousefi E, Abu-Rustum NR, Aghajanian C, Soslow RA, Ellenson LH, Weigelt B, Murali R. Momeni-Boroujeni A, et al. Among authors: aghajanian c. Gynecol Oncol. 2023 May;172:54-64. doi: 10.1016/j.ygyno.2023.03.010. Epub 2023 Mar 21. Gynecol Oncol. 2023. PMID: 36958196 Free PMC article.
Germline drivers of gynecologic carcinosarcomas.
Sia TY, Gordhandas SB, Birsoy O, Kemel Y, Maio A, Salo-Mullen E, Sheehan M, Hensley ML, Rubinstein M, Makker V, Grisham RN, O'Cearbhaill RE, Roche KL, Mueller JJ, Leitao MM Jr, Sonoda Y, Chi DS, Abu-Rustum NR, Berger MF, Ellenson LH, Latham A, Stadler Z, Offit K, Aghajanian C, Weigelt B, Mandelker D, Liu YL. Sia TY, et al. Among authors: aghajanian c. Gynecol Oncol. 2023 Jul;174:34-41. doi: 10.1016/j.ygyno.2023.04.024. Epub 2023 May 5. Gynecol Oncol. 2023. PMID: 37149903
Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer.
Sia TY, Maio A, Kemel YM, Arora KS, Gordhandas SB, Kahn RM, Salo-Mullen EE, Sheehan MA, Tejada PR, Bandlamudi C, Zhou Q, Iasonos A, Grisham RN, O'Cearbhaill RE, Tew WP, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, Chi DS, Latham AJ, Carlo MI, Murciano-Goroff YR, Will M, Walsh MF, Robson ME, Mandelker DL, Berger MF, Abu-Rustum NR, Brown CL, Offit K, Hamilton JG, Aghajanian C, Weigelt B, Stadler ZK, Liu YL. Sia TY, et al. Among authors: aghajanian c. JCO Precis Oncol. 2023 Sep;7:e2300137. doi: 10.1200/PO.23.00137. JCO Precis Oncol. 2023. PMID: 37738546
TERT promoter mutations and gene amplification in endometrial cancer.
Praiss AM, Marra A, Zhou Q, Rios-Doria E, Momeni-Boroujeni A, Iasonos A, Selenica P, Brown DN, Aghajanian C, Abu-Rustum NR, Ellenson LH, Weigelt B. Praiss AM, et al. Among authors: aghajanian c. Gynecol Oncol. 2023 Dec;179:16-23. doi: 10.1016/j.ygyno.2023.10.007. Epub 2023 Oct 25. Gynecol Oncol. 2023. PMID: 37890416
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM, Selenica P, Boerner T, Roche KL, Xiao Y, Sia TY, Maio A, Kemel Y, Sheehan M, Salo-Mullen E, Breen KE, Zhou Q, Iasonos A, Grisham RN, O'Cearbhaill RE, Chi DS, Berger MF, Kundra R, Schultz N, Ellenson LH, Stadler ZK, Offit K, Mandelker D, Aghajanian C, Zamarin D, Sabbatini P, Weigelt B, Liu YL. Kahn RM, et al. Among authors: aghajanian c. Gynecol Oncol. 2024 Jan;180:35-43. doi: 10.1016/j.ygyno.2023.11.019. Epub 2023 Dec 1. Gynecol Oncol. 2024. PMID: 38041901
Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Praiss AM, White C, Iasonos A, Selenica P, Zivanovic O, Chi DS, Abu-Rustum NR, Weigelt B, Aghajanian C, Girshman J, Park KJ, Grisham RN. Praiss AM, et al. Among authors: aghajanian c. Gynecol Oncol. 2024 Mar;182:32-38. doi: 10.1016/j.ygyno.2024.01.015. Epub 2024 Jan 20. Gynecol Oncol. 2024. PMID: 38246044
300 results